Serotonin receptor antagonists for highly emetogenic chemotherapy in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Billio, Atto ^a   Morello, Enrico ^b   Clarke, Mike J ^c  

^a Central Hospital   (Italy)

^b SPEDALI CIVILI   (Italy)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; ADULT; CHEMICALLY INDUCED DISORDER; HUMAN; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING;

DEXAMETHASONE; GRANISETRON; ISOQUINOLINE DERIVATIVE; ONDANSETRON; PALONOSETRON; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ADULT; DEXAMETHASONE; GRANISETRON; HUMANS; ISOQUINOLINES; NAUSEA; ONDANSETRON; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84897368207     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006272.pub3     Document Type: Review

References (66)

1. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Annals of Oncology 2006;17:1441-9.
2. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, et al. A double-blind randomised comparison of the anti-emetic efficacy of two intravenous dose of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy. European Journal of Cancer 1996;32A:807-13.
3. Del Favero, et al (Italian Group for Antiemetic Research). Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Annals of Oncology 1995;6:805-10.
4. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994;74:1945-52.
5. Gralla R, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single dose oral granisetron has equivalent anti-emetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. Journal of Clinical Oncology 1998;16:1568-73.
6. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, et al. Double-blind, randomised comparison of the anti-emetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Journal of Clinical Oncology 1996;14:2242-9.
7. Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin DB, et al. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. Journal of International Medical Research 2002;30:220-9.
8. Mantovani G, Maccio A, Bianchi A, Curreli L, Ghiani M, Proto E, et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941-8.
9. Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. European Journal of Cancer 1996;324:82-5.
10. Marty M, Kleisbauer JP, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis?. Anti-Cancer Drugs 1995;6 (Suppl 1):15-21.
11. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. Journal of Clinical Oncology 1995;13:1242-8.
12. Noda K, Ikeda M, Taguchi T, Yano S, Taguchi T, Shimoyama T, et al. Clinical assessment of ramosetron HCL oral preparation in the treatment of nausea and vomiting induced by cisplatin: a multicenter, randomized, parallel design, double blind comparative study with ondansetron HCL. Current Therapeutic Research 2002;63:636-48.
13. Park JO, Rha SY, Yoo NC, Kim JH, Roh JK, Min JS, et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. American Journal of Clinical Oncology (CCT) 1997;20:569-72.
14. Ruff P, Paska W, Goedhals L, Pouillart P, Rivière A, Vorobiof D, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomized, parallel-group study. Oncology 1994;51:113-8.
15. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double blind, double dummy, randomised, comparative phase III trial. Lancet Oncology 2009;10:115-24.
16. Spector JI, Lester EP, Chevlen EM, Sciortino D, Harvey JH, Whaley W, et al. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy. Oncologist 1998;3:432-8.
17. Barrajon E, de las Penas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Supportive Care in Cancer 2000;8:323-33.
18. Bianchi A, Maccio A, Correli L, et al. Comparison of granisetron vs ondansetron vs tropisetron in the prophylaxis of acute nausea and vomiting induced by high-dose cisplatin for treatment of primary head and neck cancer: an open randomized controlled trial. Annals of Oncology 1996;7 (Suppl 5):135.
19. Chua DT, Sham JST, Kwong LW, et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis. American Journal of Clinical Oncology 2000;33:185-91.
20. Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A, et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adryamicin and by high dose ifosfamide delivered in multiple-day continuous infusions. Supportive Care in Cancer 2000;8:131-3.
21. Koizumi W, Tanabe S, Nagaba S, Higuchi K, Nakayama N, Saigenji K, et al. A double-blind, crossover, randomised comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?. Chemotherapy 2003;49:316-23.
22. Nakamura H, Taira O, Kodaira S. A multicenter randomised parallel comparison of granisetron injection (GRA) with ondansetron injection (OND) in the acute emesis induced by emetogenic chemotherapy. ASCO proceedings, abstract 2324. 1999.
23. Raynov J, Raynova P, Kancheva T, Georgiev G. Antiemetic control in cancer patients treated with highly emetogenic chemotherapy. Journal of B.U.ON: official journal of the Balkan Union of Oncology 2000;5:287-91.
24. Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, et al. A randomized cross-over comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin. Journal of Cancer and Chemotherapy 1995;22:1959-67.
25. Zhaocai Yu, Wenchao Liu, Ling W, et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Supportive Care in Cancer 2008;17(1):99-102.
26. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. Journal of Clinical Oncology 2006;24:2932-47.
27. American Society of Health-System Pharmacists (ASHP). ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and paediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. American Journal of Health-System Pharmacy 1999;56:729-64.
28. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997;54:273-98.
29. Blake JC, Palmer JL, Minton NA, Burroughs AK. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. British Journal of Clinical Pharmacology 1994;35:441-3.
30. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. British Journal of Clinical Pharmacology 1994;38:273-98.
31. Blower PR. 5-HT3-receptor antagonists and the cytochrome p450 system: clinical implications. Cancer Journal 2002;8:405-14.
32. Borison HL, Mc Carthy LE. Neuropharmacology of chemotherapy induced emesis. Drugs 1983;25:8-17.
33. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. American Journal of the Medical Sciences 1987;293:34-44.
34. Cubeddu LX, Hoffmann IS, Fuenmajor NT, et al. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. Journal of Clinical Oncology 1990;8:1721-7.
35. Cubeddu LX, Hoffmann IS, Fuenmajor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. New England Journal of Medicine 1994;322:810-6.
36. Davis MP, Homsi J. The importance of cytochrome P450 monoxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442-51.
37. del Giglio A, Soares HP, Capparoz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Cancer 2000;89:2301-08.
38. Dickersin K, Scherer R, Lefebvre C. Systematic review: identifying relevant studies for systematic review. BMJ 1994;309:1286-91.
39. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Seminars in Oncology 1995;22(Suppl 10):6-18.
40. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. Journal of Clinical Pharmacology 1996;36:206-15.
41. Fozard JR, Mobarok ATM. Blockade of neuronal tryptamine receptors by metoclopramide. European Journal of Pharmacology 1978;49:109-12.
42. Gralla RJ. Controlling emesis in patients receiving chemotherapy. Recent Results in Cancer Research 1991;121:68-85.
43. Gralla RJ, Osoba D, Kris MG for the American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. Journal of Clinical Oncology 1999;9:2971-94.
44. Grunberg SM, Hansen M, Deusson R, Geling O, Hansen M, Cruciani G, et al. Incidence and impact of nausea/vomiting with modern antiemetic: perception vs. reality. Proceedings American Society of Clinical Oncology 2003;21:250a.
45. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-6.
46. Hesketh P, Grunberg S, Gralla R, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin -the aprepitant Protocol 052 Study Group. Journal of Clinical Oncology 2003;21:4112-9.
47. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
48. Hoechst Marion Russel Inc. Anzemet (dolasetron mesylate) tablets and injection. Prescribing information. Hoechst Marion Russel 1999.
49. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, issue 17:1-12.
50. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Supportive Care in Cancer 2007;15:1023-33.
51. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored anti-emetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P450 2D6 genotypes. Journal of Clinical Oncology 2002;20:2805-11.
52. Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG, et al. Antiemetic guidelines: creating a more practical treatment approach. Supportive Care in Cancer 2002;10:519-22.
53. Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Supportive Care in Cancer 1994;2:297-300.
54. Gralla RJ, Roila F, Tonato M. Consensus conference on antiemetic therapy: update. Multinational Association of Supportive Cancer. 2008.
55. Mendarte L, Aguas CM, Martinez BE, et al. Meta-analysis of granisetron versus ondansetron: efficacy and safety in the prevention of acute emesis induced by high dose cisplatin containing schedules. Medicina Clínica (Barcelona) 2000;115:456-60.
56. Moertel CG, Reitemeier RJ, Gage R. A controlled clinical evaluation of antiemetic drugs. JAMA 1963;186:116-8.
57. Navari R. Role of neurokinin-1-receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Investigations 2004;22:565-76.
58. Palmer R. Efficacy and safety of granisetron (Kytril) in two special patient population: children and adults with impaired hepatic function. Seminars in Surgical Oncology 1994;21:22-5.
59. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
60. Rhoda CL, Plosker GL, McTavish D. Tropisetron A review of its pharmacodynamic properties and therapeutic potential as an anti-emetic. Drugs 1993;46:925-43.
61. Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. European Journal of Pharmacology 1994;262:R1-R2.
62. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?. Oncology 2007;21:946-53.
63. Siegel LJ, Longo DL. The control of chemotherapy-induced emesis. Annals of Internal Medicine 1981;95:352-9.
64. Strum SB, Mc Dermed JE, Opfell RWE, et al. Intravenous metoclopramide: an effective antiemetic in cancer chemotherapy. JAMA 1982;247:2683-6.
65. Tack J. Receptors of the enteric nervous system: potential targets for drug therapy. Gut 2000;47(4):iv; 20-2.
66. The Medical Letter. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy. The Medical Letter 2004;46(179):27-8.